Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 685

1.

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group.

Ann Surg Oncol. 2017 Dec;24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10.

PMID:
29019177
2.

Growth of Infants with Intestinal Failure or Feeding Intolerance Does Not Follow Standard Growth Curves.

Morton DL, Hawthorne KM, Moore CE.

J Nutr Metab. 2017;2017:8052606. doi: 10.1155/2017/8052606. Epub 2017 Mar 5.

3.

Brain imaging of pain: state of the art.

Morton DL, Sandhu JS, Jones AK.

J Pain Res. 2016 Sep 8;9:613-24. doi: 10.2147/JPR.S60433. eCollection 2016. Review.

4.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

5.

Genome Modeling System: A Knowledge Management Platform for Genomics.

Griffith M, Griffith OL, Smith SM, Ramu A, Callaway MB, Brummett AM, Kiwala MJ, Coffman AC, Regier AA, Oberkfell BJ, Sanderson GE, Mooney TP, Nutter NG, Belter EA, Du F, Long RL, Abbott TE, Ferguson IT, Morton DL, Burnett MM, Weible JV, Peck JB, Dukes A, McMichael JF, Lolofie JT, Derickson BR, Hundal J, Skidmore ZL, Ainscough BJ, Dees ND, Schierding WS, Kandoth C, Kim KH, Lu C, Harris CC, Maher N, Maher CA, Magrini VJ, Abbott BS, Chen K, Clark E, Das I, Fan X, Hawkins AE, Hepler TG, Wylie TN, Leonard SM, Schroeder WE, Shi X, Carmichael LK, Weil MR, Wohlstadter RW, Stiehr G, McLellan MD, Pohl CS, Miller CA, Koboldt DC, Walker JR, Eldred JM, Larson DE, Dooling DJ, Ding L, Mardis ER, Wilson RK.

PLoS Comput Biol. 2015 Jul 9;11(7):e1004274. doi: 10.1371/journal.pcbi.1004274. eCollection 2015 Jul.

6.

Placebo analgesia: cognition or perception.

Morton DL, El-Deredy W, Jones AK.

Handb Exp Pharmacol. 2014;225:71-80. doi: 10.1007/978-3-662-44519-8_4.

PMID:
25304526
7.

Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.

Marzese DM, Liu M, Huynh JL, Hirose H, Donovan NC, Huynh KT, Kiyohara E, Chong K, Cheng D, Tanaka R, Wang J, Morton DL, Barkhoudarian G, Kelly DF, Hoon DS.

Pigment Cell Melanoma Res. 2015 Jan;28(1):82-93. doi: 10.1111/pcmr.12307. Epub 2014 Sep 30.

8.

DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.

Marzese DM, Scolyer RA, Roqué M, Vargas-Roig LM, Huynh JL, Wilmott JS, Murali R, Buckland ME, Barkhoudarian G, Thompson JF, Morton DL, Kelly DF, Hoon DS.

Neuro Oncol. 2014 Nov;16(11):1499-509. doi: 10.1093/neuonc/nou107. Epub 2014 Jun 26.

9.

A 20-year experience of hepatic resection for melanoma: is there an expanding role?

Faries MB, Leung A, Morton DL, Hari D, Lee JH, Sim MS, Bilchik AJ.

J Am Coll Surg. 2014 Jul;219(1):62-8. doi: 10.1016/j.jamcollsurg.2014.04.008. Epub 2014 May 10.

10.

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.

Leung AM, Lee AF, Ozao-Choy J, Ramos RI, Hamid O, O'Day SJ, Shin-Sim M, Morton DL, Faries MB, Sieling PA, Lee DJ.

Front Oncol. 2014 May 16;4:110. doi: 10.3389/fonc.2014.00110. eCollection 2014. Review.

11.

Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.

Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL, Hoon DS.

Clin Chem. 2014 Jun;60(6):873-85. doi: 10.1373/clinchem.2013.213611. Epub 2014 Apr 9.

12.

Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC Jr, Morton DL, Atkins MB, Flaherty KT, Sondak VK.

Ann Surg Oncol. 2014 Apr;21(4):1075-81. doi: 10.1245/s10434-013-3464-x. Epub 2014 Feb 15.

13.

Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB; MSLT Group.

N Engl J Med. 2014 Feb 13;370(7):599-609. doi: 10.1056/NEJMoa1310460.

14.

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.

Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC, Hata K, Wilmott JS, Murali R, Buckland ME, Shivalingam B, Thompson JF, Morton DL, Kelly DF, Hoon DS.

Hum Mol Genet. 2014 Jan 1;23(1):226-38. doi: 10.1093/hmg/ddt420. Epub 2013 Sep 6.

15.

Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system.

Leung AM, Morton DL, Ozao-Choy J, Hari DM, Shin-Sim M, Difronzo AL, Faries MB.

JAMA Surg. 2013 Sep;148(9):879-84. doi: 10.1001/jamasurg.2013.3044.

16.

Age as a prognostic factor in patients with localized melanoma and regional metastases.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.

Ann Surg Oncol. 2013 Nov;20(12):3961-8. doi: 10.1245/s10434-013-3100-9. Epub 2013 Jul 10.

17.

Late recurrence in melanoma: clinical implications of lost dormancy.

Faries MB, Steen S, Ye X, Sim M, Morton DL.

J Am Coll Surg. 2013 Jul;217(1):27-34; discussion 34-6. doi: 10.1016/j.jamcollsurg.2013.03.007. Epub 2013 May 3.

18.

B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.

Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, Zhang W, Yu H, Morton DL, Hoon DS.

J Invest Dermatol. 2013 Aug;133(8):2050-8. doi: 10.1038/jid.2013.114. Epub 2013 Mar 8.

19.

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110. Epub 2013 Feb 27.

20.

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.

Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB.

J Immunother. 2012 Nov-Dec;35(9):716-20. doi: 10.1097/CJI.0b013e31827457bd.

21.

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang HJ, Elashoff RM, Hoon DS.

J Clin Oncol. 2012 Nov 1;30(31):3819-26. doi: 10.1200/JCO.2011.40.0887. Epub 2012 Sep 24.

22.

Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques.

Kidner TB, Yoon J, Faries MB, Morton DL.

Arch Surg. 2012 Sep;147(9):871-4. doi: 10.1001/archsurg.2012.1667.

23.

Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread.

Ferris RL, Lotze MT, Leong SP, Hoon DS, Morton DL.

Clin Exp Metastasis. 2012 Oct;29(7):729-36. doi: 10.1007/s10585-012-9520-2. Epub 2012 Aug 1.

24.

A landscape of driver mutations in melanoma.

Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L.

Cell. 2012 Jul 20;150(2):251-63. doi: 10.1016/j.cell.2012.06.024.

25.

Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Morton DL.

Clin Exp Metastasis. 2012 Oct;29(7):699-706. doi: 10.1007/s10585-012-9503-3. Epub 2012 Jun 24. Review.

26.

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cochran AJ, Faries MB, Morton DL.

Ann Surg Oncol. 2012 Aug;19(8):2547-55. doi: 10.1245/s10434-012-2398-z. Epub 2012 May 31.

27.

Epitrochlear sentinel lymph nodes in melanoma: interval or independent?

Kidner TB, Yoon JL, Faries MB, Morton DL.

Am Surg. 2012 Jun;78(6):702-5.

28.

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM.

J Transl Med. 2012 Jul 4;10:83. doi: 10.1186/1479-5876-10-83.

29.

Surgery for distant melanoma metastasis.

Leung AM, Hari DM, Morton DL.

Cancer J. 2012 Mar-Apr;18(2):176-84. doi: 10.1097/PPO.0b013e31824bc981. Review.

30.

AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.

Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, Huang SK, Sim MS, Morton DL, Hoon DS.

J Invest Dermatol. 2012 Jun;132(6):1689-97. doi: 10.1038/jid.2012.36. Epub 2012 Mar 8.

31.

Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma.

Huynh KT, Takei Y, Kuo C, Scolyer RA, Murali R, Chong K, Takeshima L, Sim MS, Morton DL, Turner RR, Thompson JF, Hoon DS.

Br J Dermatol. 2012 Jun;166(6):1319-26. doi: 10.1111/j.1365-2133.2012.10867.x. Epub 2012 May 18.

32.

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS.

Ann Surg. 2012 Feb;255(2):357-62. doi: 10.1097/SLA.0b013e3182380f56.

33.

Staging of regional nodes in pulmonary malignancies.

Faries MB, Morton DL.

Ann Surg Oncol. 2012 Mar;19(3):703-5. doi: 10.1245/s10434-011-2146-9. No abstract available.

PMID:
22109733
34.

Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.

Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, Baeuerle PA, Morton DL.

J Immunother. 2011 Oct;34(8):597-605. doi: 10.1097/CJI.0b013e3182307fd8.

35.

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK.

J Clin Oncol. 2011 Jun 1;29(16):2199-205. doi: 10.1200/JCO.2010.31.5812. Epub 2011 Apr 25. Erratum in: J Clin Oncol. 2011 Jul 20;29(21):2949.

36.

Unique patterns of metastases in common and rare types of malignancy.

Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH, Cady B.

J Surg Oncol. 2011 May 1;103(6):607-14. doi: 10.1002/jso.21841. Review.

PMID:
21480255
37.

Management of popliteal sentinel nodes in melanoma.

Steen ST, Kargozaran H, Moran CJ, Shin-Sim M, Morton DL, Faries MB.

J Am Coll Surg. 2011 Jul;213(1):180-6; discussion 186-7. doi: 10.1016/j.jamcollsurg.2011.01.062. Epub 2011 Mar 26.

38.

Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes.

Wasif N, Bagaria SP, Ray P, Morton DL.

J Surg Oncol. 2011 Aug 1;104(2):111-5. doi: 10.1002/jso.21903. Epub 2011 Mar 4.

39.

Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.

Nicholl MB, Elashoff D, Takeuchi H, Morton DL, Hoon DS.

Ann Surg. 2011 Jan;253(1):116-22. doi: 10.1097/SLA.0b013e3181fca894.

40.

Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.

Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS.

Epigenetics. 2011 Mar;6(3):388-94. Epub 2011 Mar 1.

41.

Placebo analgesia as a case of a cognitive style driven by prior expectation.

Morton DL, El-Deredy W, Watson A, Jones AK.

Brain Res. 2010 Nov 4;1359:137-41. doi: 10.1016/j.brainres.2010.08.046. Epub 2010 Aug 22.

PMID:
20735999
42.

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Morton DL; MSLT Cooperative Group.

Ann Surg Oncol. 2010 Dec;17(12):3324-9. doi: 10.1245/s10434-010-1203-0. Epub 2010 Jul 8.

43.

Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Bagaria SP, Faries MB, Morton DL.

J Surg Oncol. 2010 Jun 15;101(8):669-76. doi: 10.1002/jso.21581. Review.

44.

The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions.

Cochran AJ, Binder S, Morton DL.

J Cutan Pathol. 2010 Apr;37 Suppl 1:54-9. doi: 10.1111/j.1600-0560.2010.01509.x.

PMID:
20482676
45.

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.

J Clin Oncol. 2010 May 10;28(14):2452-9. doi: 10.1200/JCO.2009.27.1627. Epub 2010 Apr 5.

46.

Cognitive changes as a result of a single exposure to placebo.

Morton DL, Brown CA, Watson A, El-Deredy W, Jones AK.

Neuropsychologia. 2010 Jun;48(7):1958-64. doi: 10.1016/j.neuropsychologia.2010.03.016. Epub 2010 Mar 21.

PMID:
20331992
47.

Predictors of occult nodal metastasis in patients with thin melanoma.

Faries MB, Wanek LA, Elashoff D, Wright BE, Morton DL.

Arch Surg. 2010 Feb;145(2):137-42. doi: 10.1001/archsurg.2009.271.

48.

High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma.

Goto Y, Arigami T, Murali R, Scolyer RA, Tanemura A, Takata M, Turner RR, Nguyen L, Nguyen T, Morton DL, Ferone S, Hoon DS.

Pigment Cell Melanoma Res. 2010 Feb;23(1):137-40. doi: 10.1111/j.1755-148X.2009.00660.x. Epub 2009 Dec 4. No abstract available.

49.

Final version of 2009 AJCC melanoma staging and classification.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK.

J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.

50.

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.

Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL.

Clin Cancer Res. 2009 Nov 15;15(22):7029-35. doi: 10.1158/1078-0432.CCR-09-1540. Epub 2009 Nov 10.

Supplemental Content

Loading ...
Support Center